- BIONOTE
- Core Technology
- R&D Center
- Biocontents R&D Department
Diagnostic antigens and immune sources for diagnostic antibodies are developing directly using gene recombination technology.
Bionote boasts outstanding expertise in designing various
recombinant raw materials, such as fragmenting or fusing immunodominant
antigens, the ability to develop optimal proteins for diagnostic antigens,
and maximized production capacity, stability, and antigenicity by expressing
recombinant proteins in various expression systems such as microorganism,
insect cells, and animal cells.
Bionote develops monoclonal antibodies with hybridoma technology which fuses B
lymphocytes producing single antibodies, and cancer cells producing indefinite cell
division. By setting various screening methods, Bionote offers the most optimized
antibody for each diagnostic needs. In addition, with its differentiated technology
in developing the recombinant antibodies in various formats such as dual antibodies and
fragment antibodies, Bionote continues to improve in its antibody production capacity,
sensitivity, and specificity.
of the stable cell line development of monoclonal cell with the protein production.
Using this technology, protein can be produced only by cell culture without using lipid
reagents, making production process more efficient. As the production capacity is improved,
the production costs are also greatly reduced. Proteins produced in monoclonal cells have
the same properties, which can increase production reproducibility
genetic analysis based on gene recombination technology, and has various enzymes applied according to the purpose of molecular diagnosis.
Various high-purity recombinant enzymes through self-developed separation process
provide strong amplification capabilities, excellent PCR fidelity and specificity.
